Qi Cao

About Qi Cao
  • A family of proteins known as the Polycomb Group (PcG) regulates gene expression in cellular development in normal cells, and is partially responsible for gene expression dysregulation in cancer.
  • PcG proteins are upregulated in prostate cancer and promote disease progression and metastasis. Therefore, these proteins are therapeutic targets.
  • One specific PcG protein is named EZH2. Inhibitors of EZH2 will be investigated for the treatment of advanced metastatic prostate cancer.

What this means for patients: Dr. Cao is working on unraveling the underlying mechanisms that lead to cancer progression and the development of treatment resistance. He will also evaluate a combination of two targeted inhibitors of EZH2 for the treatment of advanced prostate cancer.

Award

2013 Michael & Lori Milken-PCF Young Investigator

Qi Cao, PhD

Houston Methodist Research Institute

Mentor:

Arul Chinnaiyan, MD, PhD

Project Title:

A novel role for Polycomb Group proteins in androgen signaling and prostate cancer